The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused ...

A decision to possibly sell the business, which was poised to become the centerpiece of a restructuring plan, represents a shift in strategy by new company leaders.

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs it can position for partnerships.